These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18366058)

  • 21. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.
    Youde SJ; McCarthy CM; Thomas KJ; Smith KL; Man S
    Int J Cancer; 2005 Apr; 114(4):606-12. PubMed ID: 15609329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
    Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.
    Liu Y; Chiriva-Internati M; Grizzi F; Salati E; Roman JJ; Lim S; Hermonat PL
    Cancer Gene Ther; 2001 Dec; 8(12):948-57. PubMed ID: 11781657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.
    Ressing ME; van Driel WJ; Celis E; Sette A; Brandt MP; Hartman M; Anholts JD; Schreuder GM; ter Harmsel WB; Fleuren GJ; Trimbos BJ; Kast WM; Melief CJ
    Cancer Res; 1996 Feb; 56(3):582-8. PubMed ID: 8564975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
    Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
    Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
    Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
    Subbaramaiah K; Dannenberg AJ
    Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.
    Oerke S; Höhn H; Zehbe I; Pilch H; Schicketanz KH; Hitzler WE; Neukirch C; Freitag K; Maeurer MJ
    Int J Cancer; 2005 May; 114(5):766-78. PubMed ID: 15609316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
    Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
    Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
    Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
    Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
    Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells.
    Le Poole IC; ElMasri WM; Denman CJ; Kroll TM; Bommiasamy H; Lyons Eiben G; Kast WM
    Cancer Immunol Immunother; 2008 Jun; 57(6):789-97. PubMed ID: 18004565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.
    Zom GG; Welters MJ; Loof NM; Goedemans R; Lougheed S; Valentijn RR; Zandvliet ML; Meeuwenoord NJ; Melief CJ; de Gruijl TD; Van der Marel GA; Filippov DV; Ossendorp F; Van der Burg SH
    Oncotarget; 2016 Oct; 7(41):67087-67100. PubMed ID: 27564262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
    Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
    van Poelgeest MI; Nijhuis ER; Kwappenberg KM; Hamming IE; Wouter Drijfhout J; Fleuren GJ; van der Zee AG; Melief CJ; Kenter GG; Nijman HW; Offringa R; van der Burg SH
    Int J Cancer; 2006 Feb; 118(3):675-83. PubMed ID: 16108057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel intracellular nanobody against HPV16 E6 oncoprotein.
    Zhang W; Shan H; Jiang K; Huang W; Li S
    Clin Immunol; 2021 Apr; 225():108684. PubMed ID: 33549834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.